Bioxent Health and Nutrition Pvt. Ltd. stands as a leading force in third-party manufacturing, delivering premium nutraceutical products from its state-of-the-art facility in Noida, Uttar Pradesh, India. With an unwavering commitment to excellence, Bioxent partners with top-tier global companies, offering a diverse range of high-quality health supplements.
Its expansive product portfolio spans multiple health domains, including nephrology, gynaecology, orthopaedics, hepatic care, gastroenterology, cardiology, eye care, dermatology, sports nutrition, paediatric health, immunity boosters, and oncology support. Designed for maximum convenience and efficacy, these supplements come in various formats—capsules, gummies, powders, soft gels, sachets, and tablets—catering to diverse consumer needs.
Bioxent upholds the highest industry standards, holding registrations with the Food Safety and Standards Authority of India (FSSAI) and ISO 9001:2015 certifications. Its cutting-edge manufacturing facility operates under strict Good Manufacturing Practices (GMP), leveraging premium ingredients to ensure safety and efficacy in every formulation.
Driven by a team of seasoned professionals, Bioxent fosters a culture of innovation and excellence in the health supplement industry. Its dedicated research and development division continuously pioneers advanced formulations, empowering clients to launch groundbreaking products. With a portfolio of over 1,000 satisfied clients, the company has cemented its reputation as a trusted partner in the global nutraceutical sector.
Beyond manufacturing, Bioxent provides comprehensive contract manufacturing solutions, including private labelling and strategic marketing support. This holistic approach enables clients to build, develop, and expand their brands with the backing of Bioxent’s expertise and world-class infrastructure. The company’s relentless focus on quality, innovation, and customer satisfaction firmly establishes it as an industry leader.
In an exclusive conversation with The Interview World, Nirdesh Kumar Chauhan, Founder and Director of Bioxent Health and Nutrition Pvt. Ltd., delves into the evolution of India’s nutraceutical market. He highlights the transformative impact of technological advancements, the Indian pharmaceutical industry’s pivotal role in global health, and the critical policy interventions needed to accelerate the sector’s growth. Here are the key takeaways from this insightful discussion.
Q: How is the nutraceutical market evolving in the country, and what strategic interventions is your company implementing to drive growth and innovation in this space?
A: The nutraceutical market is witnessing remarkable growth, creating significant opportunities. We serve as a key manufacturing partner for companies that possess strong marketing capabilities but lack in-house production infrastructure. By bridging this gap, we enable them to bring high-quality products to market efficiently, ensuring scalability, reliability, and competitive advantage.
Q: What technological advancements are shaping the nutraceutical domain, particularly in the nutritional industry, and how is India leveraging these innovations to drive growth and competitiveness?
A: Personalized nutrition is transforming the industry. Consumers now seek customized formulations tailored to their health conditions, lifestyles, and genetic makeup. In response, companies are leveraging 3D printing to create advanced, integrative solutions. Our company is at the forefront of this innovation, investing in 3D printing technology to manufacture multi-layered tablets. These tablets allow multiple ingredients to coexist without interfering with each other, ensuring optimal efficacy and precision.
Q: How do you perceive the global growth of the pharmaceutical industry, particularly India’s expanding footprint in international markets, and what role does Indian pharma play in promoting global health and well-being?
A: India’s pharmaceutical industry is thriving on the global stage. As the world’s largest supplier of generic medicines and vaccines, it has earned the reputation of being the “pharmacy of the world.” However, the nutraceutical sector tells a different story, contributing just 1% to the global market. This gap presents a massive opportunity for Indian companies to expand their footprint. But unlocking this potential requires strong government support. Targeted policies and investments in R&D and innovation are essential to help Indian firms develop cutting-edge products and compete globally.
Q: What policy interventions are needed to strengthen and accelerate the growth of the nutraceutical sector?
A: The biggest challenge we face is the frequent policy changes by India’s regulatory authority, FSSAI. A significant gap exists between FSSAI regulations and those in developed markets like the U.S. FDA and Europe. To boost exports and streamline domestic manufacturing, the government must establish uniform standards. The current framework forces companies to navigate entirely different regulations for exports and the domestic market, creating unnecessary complexity. Aligning standards with global benchmarks will enhance India’s competitiveness and drive growth in the industry.
